Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study

OBJECTIVE: To evaluate the efficacy and safety of galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, in the preventive treatment of chronic migraine. METHODS: A phase 3, randomized, double-blind, placebo-controlled study of LY2951742 in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Detke, Holland C., Goadsby, Peter J., Wang, Shufang, Friedman, Deborah I., Selzler, Katherine J., Aurora, Sheena K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329331/
https://www.ncbi.nlm.nih.gov/pubmed/30446596
http://dx.doi.org/10.1212/WNL.0000000000006640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329331/
https://www.ncbi.nlm.nih.gov/pubmed/30446596
http://dx.doi.org/10.1212/WNL.0000000000006640

Ejemplares similares